Retatrutide and SARMs
No clinical trial has studied retatrutide combined with any SARM. No SARM is approved for human use. The FDA has issued safety warnings about SARMs. Retatrutide is not FDA approved. All rationale is anecdotal.
This page reviews what is known about combining retatrutide with selective androgen receptor modulators (SARMs): the regulatory status of each compound class, what human evidence exists, theoretical rationale discussed in online communities, and the risks that are known or plausible.
What Each Compound Is
Why People Search for This Combination
Bodybuilding and fitness communities discuss SARMs with retatrutide for body recomposition — using retatrutide's aggressive fat loss while using SARMs to preserve or build lean mass. SARMs are discussed as having anabolic effects with purportedly fewer androgenic side effects than traditional steroids. The combination is discussed anecdotally with no clinical evidence.
Human Evidence
No published clinical trial has studied retatrutide combined with any SARM. No SARM is approved for human use. The FDA has warned that SARMs are associated with serious safety risks including liver injury, heart attack, and stroke. Some SARMs have limited Phase 1/2 human data for specific medical conditions but not for body composition. Retatrutide's Phase 2 trial showed up to 24.2% mean weight loss at 48 weeks. No body composition data exists for any retatrutide-SARM combination.
Theoretical Rationale
The theoretical rationale mirrors other anabolic-GLP-1 combinations: retatrutide drives fat loss through appetite suppression and metabolic effects while SARMs' androgen receptor agonism is hypothesized to preserve or build lean mass. This is pharmacologically speculative. The interaction between triple receptor agonism and selective androgen receptor modulation is unstudied in humans.
Known and Plausible Risks
- Retatrutide: GI adverse events, heart rate increase, gallbladder effects, class-level precautions for thyroid C-cell tumors and pancreatitis
- SARMs: Liver injury (case reports), cardiovascular effects (lipid changes), hormonal suppression, potential for heart attack and stroke; FDA has issued safety warnings
- Combined: Unknown interaction risks; no safety data for any SARM combined with retatrutide exists; no SARM is approved for human use
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction with some lean mass loss. SARMs have anecdotal and limited preclinical evidence for anabolic effects. Whether any SARM would meaningfully preserve lean mass during retatrutide treatment is unknown. No body composition data exists for any retatrutide-SARM combination.
What People Are Discussing Online
Reddit communities (r/sarmssourcetalk, r/PEDs, r/Peptides) discuss various SARMs with retatrutide. Common SARMs discussed include RAD-140, LGD-4033, and Ostarine. Common claims include superior lean mass preservation versus GLP-1 alone and accelerated body recomposition. These claims are anecdotal. The FDA has specifically warned against SARMs in bodybuilding products.
Regulatory and Legal Context
No SARM is approved for human use in any jurisdiction. The FDA has issued safety warnings about SARMs including liver injury, heart attack, and stroke. Retatrutide is not FDA approved. Using two unapproved compounds simultaneously outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied retatrutide combined with any SARM. No SARM is approved for human use. No safety or efficacy data exists for any such combination.
The FDA has warned that SARMs are associated with serious safety risks including liver injury, heart attack, and stroke. No SARM is approved for human use. Long-term safety data is lacking.
Online communities discuss SARM combinations with retatrutide for body recomposition — using retatrutide for fat loss while using SARMs to preserve lean mass. This rationale is anecdotal and not supported by clinical evidence.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW